Posted on 09/06/2010 in Pharmaceutical Company Product News Eisai has published new clinical data demonstrating the effectiveness of eribulin mesylate, its investigational treatment for breast cancer.
Results from the phase III Embrace trial show that eribulin mesylate demonstrated significantly improved rates of overall median survival among recurrent and metastatic breast cancer patients, when compared to alternative treatments chosen by physicians.
This means the drug met its overall efficacy endpoint, while encouraging results were also recorded in terms of the secondary objectives of progression free survival and overall response rate.
Eribulin mesylate is currently being considered for regulatory approval in a number of territories, including Europe, the US and Japan.
It is hoped that the treatment will help to combat metastatic breast cancer, with only one in five sufferers of the disease currently surviving for more than five years.
This data was presented at the American Society of Clinical Oncology annual meeting, where Eisai also highlighted trial data on new treatments for T-cell lymphoma and non-small cell lung cancer.Other news stories from 09/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
